Solar Medical & Chemical Limited Filleted accounts for Companies House (small and micro)

COMPANY REGISTRATION NUMBER: 10648817

Solar Medical & Chemical Limited

Filleted Unaudited Financial Statements

31 August 2025

Solar Medical & Chemical Limited

Financial Statements

Year ended 31 August 2025

Contents	Page

Statement of financial position	1

Notes to the financial statements	3

Solar Medical & Chemical Limited

Statement of Financial Position

31 August 2025

	2025	2024
Note	£	£

Fixed assets

Tangible assets	7	136,288	128,691

Current assets

Stocks		387,042	396,438
Debtors	8	317,002	256,631
Cash at bank and in hand		4,543	7,179
		---------	---------
		708,587	660,248

Creditors: amounts falling due within one year	9	786,719	594,644
		---------	---------
Net current (liabilities)/assets		( 78,132)	65,604
		---------	---------
Total assets less current liabilities		58,156	194,295

Creditors: amounts falling due after more than one year	10	64,045	99,945
		--------	---------
Net (liabilities)/assets		( 5,889)	94,350
		--------	---------

Capital and reserves

Called up share capital	100	100
Share premium account	55,000	55,000
Profit and loss account	( 60,989)	39,250
	--------	--------
Shareholder (deficit)/funds	( 5,889)	94,350
	--------	--------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.

For the year ending 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;

- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

Solar Medical & Chemical Limited

Statement of Financial Position (continued)

31 August 2025

These financial statements were approved by the board of directors and authorised for issue on 27 May 2026 , and are signed on behalf of the board by:

Mr R.L.J. Powell
Director

Company registration number: 10648817

Solar Medical & Chemical Limited

Notes to the Financial Statements

Year ended 31 August 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Unit B1a Avondale Business Park, Avondale Way, Cwmbran, NP44 1XE.

2. Statement of compliance

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The accounts have been prepared on the going concern basis. The directors have reviewed the financial position of the company including projections for future trading and obtained suitable assurances from the lenders.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Income tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Operating leases

Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.

Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Plant and machinery	-	8% straight line
Motor vehicles	-	20% straight line

Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stock to its present location and condition.

Finance leases and hire purchase contracts

Assets held under finance leases and hire purchase contracts are recognised in the statement of financial position as assets and liabilities at the lower of the fair value of the assets and the present value of the minimum lease payments, which is determined at the inception of the lease term. Any initial direct costs of the lease are added to the amount recognised as an asset. Lease payments are apportioned between the finance charges and reduction of the outstanding lease liability using the effective interest method. Finance charges are allocated to each period so as to produce a constant rate of interest on the remaining balance of the liability.

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 8 (2024: 8 ).

5. Tax on loss

Major components of tax income

		Period from
	Year to	1 Apr 23 to
	31 Aug 25	31 Aug 24
	£	£

Current tax:

Research and development tax credit	–	(36,940)

Deferred tax:

Origination and reversal of timing differences	( 35,830)	–
	--------	--------
Tax on loss	( 35,830)	( 36,940)
	--------	--------

6. Dividends

Dividends paid during the year (excluding those for which a liability existed at the end of the prior year):

	2025	2024
	£	£
Dividends on equity shares	–	1,500
	----	-------

7. Tangible assets

	Plant and machinery	Motor vehicles	Total
	£	£	£
Cost
At 1 September 2024	249,602	67,791	317,393
Additions	40,190	–	40,190
	---------	--------	---------
At 31 August 2025	289,792	67,791	357,583
	---------	--------	---------
Depreciation
At 1 September 2024	138,950	49,752	188,702
Charge for the year	23,183	9,410	32,593
	---------	--------	---------
At 31 August 2025	162,133	59,162	221,295
	---------	--------	---------
Carrying amount
At 31 August 2025	127,659	8,629	136,288
	---------	--------	---------
At 31 August 2024	110,652	18,039	128,691
	---------	--------	---------

Finance leases and hire purchase contracts

Included within the carrying value of tangible assets are the following amounts relating to assets held under finance leases or hire purchase agreements:

	Motor vehicles
	£
At 31 August 2025	8,629
	-------
At 31 August 2024	14,079
	--------

8. Debtors

	2025	2024
	£	£
Trade debtors	280,367	249,075
Deferred tax asset	35,830	–
Prepayments and accrued income	805	7,556
	---------	---------
	317,002	256,631
	---------	---------

9. Creditors: amounts falling due within one year

	2025	2024
	£	£
Bank loans and overdrafts	343,787	240,141
Trade creditors	230,975	200,153
Accruals and deferred income	4,683	1,440
Social security and other taxes	193,264	128,034
Obligations under finance leases and hire purchase contracts	5,995	5,692
Director loan accounts	8,015	19,184
	---------	---------
	786,719	594,644
	---------	---------

10. Creditors: amounts falling due after more than one year

	2025	2024
	£	£
Bank loans and overdrafts	57,731	87,637
Obligations under finance leases and hire purchase contracts	6,314	12,308
	--------	--------
	64,045	99,945
	--------	--------

11. Finance leases and hire purchase contracts

The total future minimum lease payments under finance leases and hire purchase contracts are as follows:

	2025	2024
	£	£
Not later than 1 year	6,649	6,649
Later than 1 year and not later than 5 years	6,649	13,298
	--------	--------
	13,298	19,947
Less: future finance charges	( 990)	( 1,947)
	--------	--------
Present value of minimum lease payments	12,308	18,000
	--------	--------

12. Contingencies

A debenture registered on 27th March 2023 by Ecapital Commercial Finance Limited provides a fixed charge over any company debt and a floating charge over the company's property and assets present and future on all monies due or to become due from the company to the chargee on any account whatsoever.

13. Director's advances, credits and guarantees

During the year the director entered into the following advances and credits with the company:

	2025
	Balance brought forward	Advances/ (credits) to the director	Balance outstanding
	£	£	£
Mr R.L.J. Powell	( 19,184)	11,169	( 8,015)
	--------	--------	-------

	2024
	Balance brought forward	Advances/ (credits) to the director	Balance outstanding
	£	£	£
Mr R.L.J. Powell	( 3,569)	( 15,615)	( 19,184)
	-------	--------	--------

14. Related party transactions

The company was under the control of Mr R.L.J. Powell throughout the period. No other transactions with related parties were undertaken such as are required to be disclosed under Financial Reporting Standard 102.